NCT01727973View on ClinicalTrials.gov

Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Graves OphthalmopathyGraves DiseaseEye DiseasesThyroid DiseasesEndocrine System DiseasesEye Diseases, HereditaryHyperthyroidismAutoimmune DiseasesImmune System Diseases
Interventions
DRUG

Doxycycline

Tab. Doxycycline 50 mg PO per day for 12 weeks

Trial Locations (1)

510060

Zhongshan Ophthalmic Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy | Biotech Hunter | Biotech Hunter